
New MCL research spotlights BTK inhibitors, CAR-T advances, MRD-guided trials, and TP53-driven risk, reshaping frontline and relapse care.

Your AI-Trained Oncology Knowledge Connection!


New MCL research spotlights BTK inhibitors, CAR-T advances, MRD-guided trials, and TP53-driven risk, reshaping frontline and relapse care.

Marginal Zone Lymphoma experts discussed recent advancements in all areas of MZL, while calling attention to gaps in knowledge in the 2024 MZL Scientific Workshop.

In 2023, the Lymphoma Research Foundation hosted the Mantle Cell Lymphoma Scientific Consortium and Workshop to discuss treatment advancements in the field.